Enlivex Therapeutics (NASDAQ:ENLV) reported quarterly earnings of $26.83 per share which beat the analyst consensus estimate of $(0.13) by 20738.46 percent. This is a 12295.45 percent increase over losses of $(0.22) per share from the same period last year.